Lonza Group AG (LONN.SW)

543,40 +7,40 (+1,38%) Börsenschluss: 05:31PM CEST

Lonza Group AG

Muenchensteinerstrasse 38
Basel 4002
Switzerland
41 61 316 81 11
https://www.lonza.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Pierre-Alain Ruffieux Ph.D.	Chief Exec. Officer	2,64M	N/A	1969
Mr. Philippe Deecke	Chief Financial Officer	N/A	N/A	1972
Ms. Maria Soler Nunez	Head of Group Operations	N/A	N/A	N/A
Mr. Dirk Oehlers	VP of Investor Relations	N/A	N/A	N/A
Mr. Andreas Bohrer	Group Gen. Counsel & Company Sec.	N/A	N/A	N/A
Ms. Victoria Morgan	Head of External Communications	N/A	N/A	N/A
Ms. Jennifer Clancy	Sr. Director of Global Marketing	N/A	N/A	N/A
Dr. Caroline Barth M.D.	Chief HR Officer	N/A	N/A	1972
Ms. Constance Ward	Head of External Communications	N/A	N/A	N/A
Dr. Sanna Fowler	Head of External Communications	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CHF.

Beschreibung

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.

Corporate Governance

Lonza Group AGs ISS Governance QualityScore, Stand 1. März 2023, lautet 1. Die grundlegenden Scores sind Audit: 6, Vorstand: 1, Shareholderrechte: 1, Kompensation: 2.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.